

Andrey U Kulikov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5757827/publications.pdf>

Version: 2024-02-01

237
papers

150
citations

1478505

6
h-index

1474206

9
g-index

241
all docs

241
docs citations

241
times ranked

132
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation. <i>Farmakoekonomika</i> , 2022, 15, 73-86.	1.2	1
2	Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 1-17.	0.5	1
3	Mathematical Modeling for Financial Analysis of an Enterprise: Motivating of Not Open Innovation. <i>Journal of Open Innovation: Technology, Market, and Complexity</i> , 2021, 7, 79.	5.2	12
4	Improving the Development Technology of an Oil and Gas Company Using the Minimax Optimality Criterion. <i>Energies</i> , 2021, 14, 3177.	3.1	9
5	DRUG PROVISION MANAGEMENT TO PROVIDE BETTER ACCESS TO THE HIGH COST TREATMENT AND IMPROVE OUTCOMES – EXAMPLE OF MUCOPOLYSACCHARIDOSIS TYPE II. <i>Pharmacoeconomics Theory and Practice</i> , 2021, 9, 6-11.	0.1	0
6	Optimization of the Structure of the Investment Portfolio of High-Tech Companies Based on the Minimax Criterion. <i>Energies</i> , 2021, 14, 4647.	3.1	12
7	Patient Flows, Patient Distribution Computations and Medicines Accounting in the Pharmacoeconomic Models Through Procurement Perspective. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 673-680.	1.9	0
8	Pharmacoeconomic evaluation of various treatment options for respiratory distress syndrome in newborns. <i>Voprosy Ginekologii, Akusherstva I Perinatologii</i> , 2021, 20, 155-161.	0.3	1
9	PNS36 ECONOMIC EVALUATION OF TOBACCO SMOKING EFFECTS IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2020, 23, S290.	0.3	0
10	PDB42 BUDGET IMPACT ANALYSIS OF SENSOR-AUGMENTED PUMP IN TYPE 1 DIABETES MELLITUS COMPARED WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2020, 23, S115-S116.	0.3	0
11	PDB40 COST-EFFECTIVENESS ANALYSIS OF SENSOR-AUGMENTED PUMP IN TYPE 1 DIABETES MELLITUS COMPARED WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2020, 23, S115.	0.3	0
12	PNS12 INTEGRAL SCALE ASSESSMENT FOR PHARMACOECONOMIC EVALUATION FOR REIMBURSEMENT DECISION-MAKING IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2020, 23, S286.	0.3	0
13	PRS54 BUDGET IMPACT ANALYSIS OF THE DUPILUMAB IN THE TREATMENT PATIENTS WITH SEVERE BRONCHIAL ASTHMA IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2020, 23, S358.	0.3	0
14	PIH64 ADJUSTED INDIRECT COMPARISON OF THE MEDICINES USING IN CONTROLLED OVARIAN STIMULATION FOR ASSISTED REPRODUCTIVE TECHNOLOGY. <i>Value in Health</i> , 2020, 23, S163-S164.	0.3	0
15	Results of a Sociological Survey on the Needs of Drug Safety Monitoring Specialists for Information on the Creation of the Pharmacovigilance System Master File. <i>Safety and Risk of Pharmacotherapy</i> , 2020, 8, 84-89.	0.2	1
16	PHARMACOECONOMIC ANALYSIS OF THE SELF-MONITORING BLOOD GLUCOSE USE IN THE DIABETES MELLITUS PATIENTS TREATMENT IN THE RUSSIAN FEDERATION. <i>Pharmacoeconomics Theory and Practice</i> , 2020, 8, 17-21.	0.1	0
17	PHARMACOECONOMIC EVALUATION OF BIOLOGICAL DRUGS IN THE CROHN'S DISEASE TREATMENT IN THE RUSSIAN FEDERATION. <i>Pharmacoeconomics Theory and Practice</i> , 2020, 8, 6-16.	0.1	0
18	BUDGET IMPACT ANALYSIS OF SECUKINUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS IN THE RUSSIAN FEDERATION. <i>Pharmacoeconomics Theory and Practice</i> , 2020, 8, 23-28.	0.1	0

#	ARTICLE	IF	CITATIONS
19	METHODOLOGICAL ISSUES OF COMPUTATIONS OF THE ENTRY AND DISTRIBUTION OF PATIENTS AND DETERMINING THE COURSE DOSE OF DRUGS IN PHARMACOECONOMIC MODELS. <i>Pharmacoeconomics Theory and Practice</i> , 2020, 8, 6-10.	0.1	0
20	PRS2 COST ANALYSIS FOR THE TREATMENT OF SEVERE UNCONTROLLED BRONCHIAL ASTHMA IN THE RUSSIAN FEDERATION. <i>Value in Health Regional Issues</i> , 2019, 19, S77.	1.2	0
21	PMD19 ECONOMIC EVALUATION OF CATARACT PHACOEMULSIFICATION IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S672-S673.	0.3	0
22	PMD59 COST-EFFECTIVENESS EVALUATION OF PHACOEMULSIFICATION PLATFORMS IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S679.	0.3	0
23	PDB22 BUDGET IMPACT ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S575.	0.3	0
24	PDB12 BUDGET IMPACT ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN TYPE 1 DIABETES MELLITUS COMPARED WITH MULTIPLE DAILY INJECTIONS IN THE RUSSIAN FEDERATION. <i>Value in Health Regional Issues</i> , 2019, 19, S30.	1.2	0
25	PIH3 BUDGET IMPACT ANALYSIS OF MEDICINES FOR CONTROLLED OVARIAN STIMULATION IN THE TREATMENT OF INFERTILITY IN PATIENTS WITH AN SUBOPTIMAL OVARIAN RESPONSE IN THE RUSSIAN FEDERATION. <i>Value in Health Regional Issues</i> , 2019, 19, S36.	1.2	0
26	PSY13 BUDGET IMPACT ANALYSIS OF TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH BARICITINIB IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S903.	0.3	0
27	PSY20 COST-EFFECTIVENESS ANALYSIS OF SECLIKINUMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S905.	0.3	0
28	PDB4 COST-EFFECTIVENESS ANALYSIS OF SWITCHING FROM ALOGLIPTIN TO VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES. <i>Value in Health Regional Issues</i> , 2019, 19, S29.	1.2	0
29	PRO40 BUDGET IMPACT ANALYSIS OF IDURSULFASE BETA IN THE TREATMENT MUCOPOLYSACCHARIDOSIS TYPE II IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S848.	0.3	0
30	PCV71 INDIRECT COMPARISON OF NEUROPROTECTORS IN THE TREATMENT OF ISCHEMIC STROKE IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S554.	0.3	1
31	PDB10 COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN TYPE 1 DIABETES MELLITUS COMPARED WITH MULTIPLE DAILY INJECTIONS IN THE RUSSIAN FEDERATION. <i>Value in Health Regional Issues</i> , 2019, 19, S30.	1.2	0
32	PDB29 COST-EFFECTIVENESS ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S577.	0.3	0
33	PDB11 BUDGET IMPACT ANALYSIS OF SWITCHING FROM ALOGLIPTIN TO VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES. <i>Value in Health Regional Issues</i> , 2019, 19, S30.	1.2	0
34	PIH2 COST-EFFECTIVENESS ANALYSIS OF MEDICINES FOR CONTROLLED OVARIAN STIMULATION IN THE TREATMENT OF INFERTILITY IN PATIENTS WITH AN SUBOPTIMAL OVARIAN RESPONSE IN THE RUSSIAN FEDERATION. <i>Value in Health Regional Issues</i> , 2019, 19, S36.	1.2	0
35	Comparative analysis of the methodology of pharmacoeconomic assessment according to the origin (dated 08.28.2014) and the current (dated 10.29.2018) version of the government degree of the Russian Federation №871. <i>Pharmacoeconomics Theory and Practice</i> , 2019, 7, 7-16.	0.1	2
36	Learning Needs as a Reflection of Professional Interests among Health Experts. <i>Safety and Risk of Pharmacotherapy</i> , 2019, 7, 44-52.	0.2	1

#	ARTICLE	IF	CITATIONS
37	Pharmacoeconomic evaluation of drugs used in enzyme replacement therapy mucopolysaccharidosis type II. <i>Pharmacoeconomics Theory and Practice</i> , 2019, 7, 10-15.	0.1	2
38	Health technology assessment of cataract phacoemulsification platforms. <i>Pharmacoeconomics Theory and Practice</i> , 2019, 7, 10-17.	0.1	0
39	Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease. <i>Russian Journal of Cardiology</i> , 2019, , 76-86.	1.4	2
40	PRS50 - COST-EFFECTIVENESS ANALYSIS OF SURFACTANT THERAPY FOR THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME NEWBORN IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2018, 21, S412.	0.3	2
41	PRS48 - COST EFFECTIVENESS ANALYSIS OF VILANTEROL/FLUTICASONE FUROATE FOR ASTHMA TREATMENT IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2018, 21, S412.	0.3	0
42	Pharmacoeconomic analysis of therapy with reslizumab in severe eosinophilic asthma. <i>Pulmonologiya</i> , 2018, 28, 50-60.	0.8	3
43	Pharmacoeconomic evaluation of Secukinumab use as a first-line biologic in patients with psoriatic arthritis. <i>Pharmacoeconomics Theory and Practice</i> , 2018, 6, 20-28.	0.1	2
44	Pharmacoeconomic analysis of a medicinal product neoton (phosphocreatine) in perioperative management of cardiac surgery patients with extracorporeal circulation, with ischemic heart disease or with chronic heart insufficiency. <i>Pharmacoeconomics Theory and Practice</i> , 2018, 5, 77-80.	0.1	1
45	Pharmacoeconomic analysis of infertility treatment in women with a suboptimal ovarian response. <i>Akusherstvo I Ginekologiya (Russian Federation)</i> , 2018, 6_2018, 77-84.	0.3	1
46	Pharmacoeconomic analysis of vildagliptin in the treatment of type 2 diabetes mellitus. <i>Pharmacoeconomics Theory and Practice</i> , 2018, 6, 5-10.	0.1	0
47	Pharmacoeconomic evaluation of the drug follitropin- alpha+lutropin-alpha (Pergoveris) using in treatment of infertile women with suboptimal ovarian response in the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2018, 6, 11-16.	0.1	0
48	Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making. <i>Value in Health Regional Issues</i> , 2017, 13, 61-66.	1.2	11
49	Cost-Effectiveness Analysis Of 10% Intravenous Immunoglobulin Compared With Plasma Exchange In Treatment Of Children With Guillain-Barré Syndrome In Russia. <i>Value in Health</i> , 2017, 20, A753.	0.3	0
50	Budget Impact Analysis of Same And Mixed Budesonide And Formoterol Inhalers In The Treatment of Asthma In Russian Federation. <i>Value in Health</i> , 2017, 20, A641.	0.3	0
51	Cost-Effectiveness Analysis of Standard Therapy with Phosphocreatine VS Standard Therapy In Perioperative Management of Cardiac Surgery Patients With Extracorporeal Circulation, With Ischemic Heart Disease or With Chronic Heart Insufficiency. <i>Value in Health</i> , 2017, 20, A616-A617.	0.3	0
52	Comparison of Budesonide Inhalers For Treatment of Asthma In Adults And Adolescents In Russian Federation: Cost Effectiveness Analysis. <i>Value in Health</i> , 2017, 20, A646.	0.3	0
53	Cost Utility Analysis of Two Budesonide Inhalers For Treatment of Asthma In Children In Russian Federation. <i>Value in Health</i> , 2017, 20, A646-A647.	0.3	0
54	Cost-Minimization Analysis of 10% Intravenous Immunoglobulin In Treatment Of Primary Immunodeficiencies In Children In The Russian Federation. <i>Value in Health</i> , 2017, 20, A551.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Economic Evaluation of 10% Intravenous Immunoglobulin In Treatment of Primary Immunodeficiencies In Adults In The Russian Federation. Value in Health, 2017, 20, A551.	0.3	0
56	Pharmacoeconomic analysis of Hemosfer (iron III - hydroxide dextran) in the treatment of iron deficiency anemia for chronic kidney disease patients. Pharmacoeconomics Theory and Practice, 2017, 5, 62-64.	0.1	0
57	Pharmacoeconomic analysis of eporatio for treatment of anemia in cancer patients. Pharmacoeconomics Theory and Practice, 2017, 5, 72-77.	0.1	0
58	Pharmacoeconomic analysis of eporatio for treatment of anemia in cancer patients. Pharmacoeconomics Theory and Practice, 2017, 5, 72-77.	0.1	0
59	Pharmacoeconomic analysis of long-term effects of more widespread use of in vitro fertilization in infertility treatment at the regional and federal level from the standpoint of society at large in the Russian Federation. Pharmacoeconomics Theory and Practice, 2017, 5, 41-46.	0.1	0
60	Pharmacoeconomic analysis of nivolumab in treatment of nonresectable stage III-IV melanoma among treatment-naive BRAF-mutated patients in the Russian Federation. Pharmacoeconomics Theory and Practice, 2017, 5, 47-47.	0.1	1
61	Assessment of clinical and economic effectiveness of apremilast in the treatment of psoriatic arthritis. Pharmacoeconomics Theory and Practice, 2017, 5, 35-40.	0.1	0
62	Pharmacoeconomic analysis of combination of daclatasvir and sofosbuvir in treatment of chronic hepatitis C(genotype 3) in the Russian Federation: among treatmentexperienced patients. Pharmacoeconomics Theory and Practice, 2017, 5, 28-28.	0.1	1
63	Pharmacoeconomic analysis of the use of dapagliflozin for treatment of type 2 diabetes mellitus. Pharmacoeconomics Theory and Practice, 2017, 5, 29-33.	0.1	0
64	Pharmacoeconomic analysis of continuation of use of symbicort [®] turbuhaler [®] as the sole inhaler for bronchial asthma therapy. Pharmacoeconomics Theory and Practice, 2017, 5, 45-53.	0.1	0
65	Validation of the "budget impact analysis" model of the introduction of dolutegravir drug into the public procurement of antiretroviral drugs in the Russian Federation. Pharmacoeconomics Theory and Practice, 2017, 5, 64-66.	0.1	0
66	Pharmacoeconomic analysis of sofosbuvir for the treatment of chronic hepatitis c (genotype 1) in the russian federation. Pharmacoeconomics Theory and Practice, 2017, 5, 51-61.	0.1	0
67	A comparative pharmacoeconomic analysis of impact of alcohol consumption on russia's economy		

#	ARTICLE	IF	CITATIONS
73	Budget Impact Analysis of Acclidinium Bromide In The Treatment of Chronic Obstructive Pulmonary Disease. Value in Health, 2016, 19, A550.	0.3	0
74	Budget Impact Analysis of Standard Care with Serelaxin in Treatment of Patients with Acute Decompensated Heart Failure. Value in Health, 2016, 19, A653.	0.3	0
75	Cost-Effectiveness Analysis of Lipegfilgrastim in Prophylaxis of Febrile Neutropenia in Cancer Patients. Value in Health, 2016, 19, A736.	0.3	0
76	Cost-Effectiveness Analysis Of Daclatasvir With Asunaprevir In Treatment Of Chronic Hepatitis C In The Russian Federation. Value in Health, 2016, 19, A415.	0.3	0
77	Cost-Effectiveness Analysis Of Daclatasvir With Asunaprevir Vs Paritaprevir/Ritonavir/Ombitasvir With Dasabuvir In Treatment Of Chronic Hepatitis C In The Russian Federation. Value in Health, 2016, 19, A415-A416.	0.3	0
78	Budget Impact Analysis of Sucroferic Oxyhydroxide in Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease. Value in Health, 2016, 19, A517.	0.3	0
79	Cost-Effectiveness Analysis of Sucroferic Oxyhydroxide in Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease. Value in Health, 2016, 19, A518.	0.3	0
80	Cost-Effectiveness Analysis Of Formoterol For Asthma Treatment In Russian Federation. Value in Health, 2016, 19, A115-A116.	0.3	0
81	Budget Impact Analysis Of Budesonide In The Treatment Of Asthma In Adult Population In Russian Federation. Value in Health, 2016, 19, A113.	0.3	0
82	Budget Impact Analysis of Medical Care for Chronic Renal Disease Patients in Need of Renal Replacement Therapy Via Peritoneal Dialysis and Hemodialysis in the Russian Health Care Environment. Value in Health, 2016, 19, A130.	0.3	2
83	Cost-Effectiveness Analysis of Medical Care for Chronic Renal Disease Patients in Need of Renal Replacement Therapy Via Peritoneal Dialysis and Hemodialysis in the Russian Health Care Environment. Value in Health, 2016, 19, A131.	0.3	0
84	Pharmacoeconomic analysis of the use of granulocyte colonystimulating factor drugs in prophylaxis of febrile neutropenia in cancer patients under healthcare settings in the Russian Federation. Pharmacoeconomics Theory and Practice, 2016, 4, 195-201.	0.1	1
85	Pharmacoeconomic analysis of combination of medicines daclatasvir and asunaprevir in treatment of chronic hepatitis C in the Russian Federation. Pharmacoeconomics Theory and Practice, 2016, 4, 131-138.	0.1	0
86	Pharmacoeconomic analysis of combination of medicines daclatasvir and asunaprevir in treatment of chronic hepatitis C in the Russian Federation. Pharmacoeconomics Theory and Practice, 2016, 4, 131-138.	0.1	0
87	Pharmacoeconomic evaluation of pomalidomide (imnovid) use in treatment of patients with relapsed or refractory multiple myeloma who have received at least two lines of therapy comprising lenalidomide and bortezomib. Pharmacoeconomics Theory and Practice, 2016, 4, 157-164.	0.1	1
88	Pharmacoeconomic analysis of medicinal drug foscarnet in patients with cytomegalovirus retinitis. Pharmacoeconomics Theory and Practice, 2016, 4, 105-110.	0.1	0
89	Pharmacoeconomic analysis of medicinal drug foscarnet in patients with cytomegalovirus retinitis. Pharmacoeconomics Theory and Practice, 2016, 4, 105-110.	0.1	0
90	Pharmacoeconomic analysis of medicinal drug foscarnet in patients with cytomegalovirus retinitis. Pharmacoeconomics Theory and Practice, 2016, 4, 105-110.	0.1	0

#	ARTICLE	IF	CITATIONS
91	Pharmacoeconomic analysis of lapatinib treatment in metastatic breast cancer with HER2+ overexpression. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 62-69.	0.1	0
92	Pharmacoeconomic analysis of use of specialized health food line «MDMIL PKU» in children from birth compared with diet therapy, started in later periods. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 44-52.	0.1	0
93	Pharmacoeconomic analysis of metformin extended-release form using in diabetes mellitus type 2 treatment. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 96-101.	0.1	0
94	Pharmacoeconomic evaluation of dabrafenib in patients with unresectable or metastatic melanoma with BRAF V600 mutation. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 110-115.	0.1	0
95	Pharmacoeconomic analysis of the medicinal product «Dipaxone-40» in treating multiple sclerosis. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 35-39.	0.1	1
96	A pharmacoeconomic analysis of dual antiplatelet therapy with acetylsalicylic acid and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 29-33.	0.1	0
97	Pharmacoeconomic analysis of trastuzumab application for subcutaneous administration compared to intravenous administration in the treatment of HER2-positive breast cancer in regions of the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 70-74.	0.1	0
98	Pharmacoeconomic analysis of cellex application in the treatment of cerebrovascular accident. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 61-63.	0.1	3
99	Budget impact analysis of ipilimumab usage in patients with metastatic melanoma. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 74-77.	0.1	0
100	Analysis of costs of medicinal product lanreotide (somatuline® autogel®) in the treatment of pnet degree grade 1 or 2 (with tumor proliferation index [KI-67] < 10%), in adult patients with non-functioning non-metastatic or metastatic tumors. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 25-29.	0.1	0
101	Pharmacoeconomic assessment of hepatoprotectors used for prevention of developing post-resection acute liver failure after extensive hemihepatectomy due to colorectal cancer metastases. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 62-68.	0.1	0
102	Analysis of pharmacoeconomic and clinical economic studies published in the scientific electronic library «LIBRARY.RU» (RSCI) for the period from 2005 to 2015. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 60-108.	0.1	2
103	Relative value assessment of ipilimumab usage in patients with metastatic melanoma. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 128-134.	0.1	0
104	Pharmacoeconomic Analysis of the Inclusion of Rivaroxaban in the Current Algorithms Prevention of the Stroke in Patients With Atrial Fibrillation. <i>Kardiologiya</i> , 2016, 11_2016, 71-77.	0.7	1
105	«Cost Of Illness» Analysis Of Chronic Kidney Disease In The Entire Population Of The Russian Federation. <i>Value in Health</i> , 2015, 18, A187.	0.3	0
106	Budget Impact Analysis of Canacinumab In The Treatment of Patients With Muckle-Wells Syndrome In The Russian Federation. <i>Value in Health</i> , 2015, 18, A663.	0.3	1
107	Budget Impact Analysis of Botulinum Toxin Type A Treatment for Cerebral Palsy In The Russian Federation. <i>Value in Health</i> , 2015, 18, A752.	0.3	1
108			

#	ARTICLE	IF	CITATIONS
109	Cost Effectiveness Analysis Of Budesonid Easyhaler In The Treatment Of Asthma In Children In The Russian Federation. Value in Health, 2015, 18, A501.	0.3	0
110	Pharmacoeconomic Analysis of Urothelial Transitional Cell Cancer Treatment with Vinflunine in Patients Resistant to the Platinum-Based Treatment Regimes. Value in Health, 2015, 18, A443-A444.	0.3	0
111	Budget Impact Analysis of Blood Clotting Factor Concentrates In The Treatment of Von Willebrand Disease. Value in Health, 2015, 18, A663.	0.3	0
112	Budget Impact Analysis of Botulinum Toxin Type A In Treatment of Post-Stroke Spasticity In The Russian Federation. Value in Health, 2015, 18, A157.	0.3	0
113	Budget Impact Analysis of Dasatinib as a Second-Line Therapy in Patients with Chronic Myelogenous Leukemia (Cml) in the Russian Federation. Value in Health, 2015, 18, A441-A442.	0.3	1
114	Cost-Effectiveness Analysis Of Obinutuzumab/Chlorambucil Vs Rituximab/Chlorambucil In Treatment Of Chronic Lymphocytic Leukemia. Value in Health, 2015, 18, A460.	0.3	3
115	Pharmacoeconomic Evaluation Of The Use Of Trastuzumab For Subcutaneous Administration Compared To Intravenous Dosage Form In The Treatment Of Breast Cancer. Value in Health, 2015, 18, A463.	0.3	1
116	Cost-Effectiveness Analysis of Canacinumab In The Treatment of Patients Suffering From Systemic Juvenile Idiopathic Arthritis In Russian Federation. Value in Health, 2015, 18, A646.	0.3	0
117	Cost-Effectiveness Analysis of Botulinum Toxin Type a Treatment for Cerebral Palsy. Value in Health, 2015, 18, A734.	0.3	1
118	Cost-Effectiveness Analysis of Cerebrolysin In The Treatment of Patients With Acute Ischemic Stroke Moderate and Severe Degrees of Severity In The Russian Federation. Value in Health, 2015, 18, A705.	0.3	5
119	Budget Impact Analysis of Cerebrolysin In The Treatment of Acute Ischemic Stroke of Moderate and Severe Degrees of Severity In The Russian Federation. Value in Health, 2015, 18, A699.	0.3	1
120	Pharmacoeconomic Study Of The Use Of Rituximab For Subcutaneous Administration In The Treatment Of Follicular Lymphoma. Value in Health, 2015, 18, A463.	0.3	1
121	Modeling of Societal Costs Under Different Treatment Schemes of Post-Stroke Spasticity In The Russian Federation. Value in Health, 2015, 18, A157-A158.	0.3	0
122	Pharmacoepidemiologic Modeling of Treatment Hiv-Infected Patients With Rilpivirine/ Tenofovir/ Emtricitabin (Single Tablet Regimen) in Russia. Value in Health, 2015, 18, A589.	0.3	0
123	Modeling of Using Rilpivirine/ Tenofovir/ Emtricitabine In Treatment of Naïve Hiv-1 Infected Patiens. Value in Health, 2015, 18, A578.	0.3	0
124	Potential Long-Term Cost Savings In Treatment of Naïve Hiv-Infected Patients With Rilpivirine/ Tenofovir/ Emtricitabine (Single Tablet Regimen) In The Russian Federation. Value in Health, 2015, 18, A581.	0.3	0
125	Budget Impact Analysis Of Formoterol Easyhaler In The Treatment Of Asthma In Children In The Russian Federation. Value in Health, 2015, 18, A497.	0.3	0
126	Pharmacoeconomic analysis of the use of the kuvan drug product in phenylketonuric patients. Pharmacoeconomics Theory and Practice, 2015, 3, 20-21.	0.1	2

#	ARTICLE	IF	CITATIONS
127	Pharmacoeconomic analysis to compare subcutaneous versus intravenous mabthera® (rituximab) in patients with follicular lymphoma. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 17-19.	0.1	2
128	Pharmacoeconomic analysis of the medicinal product javlor (vinflunine) in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 86-90.	0.1	1
129	Pharmacoeconomic analysis of different types of treatment for spastic forms of cerebral palsy. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 71-78.	0.1	2
130	Pharmacoeconomic analysis of the medicinal product javlor (vinflunine) in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 86-90.	0.1	1
131	Pharmacoeconomic analysis of different types of treatment for spastic forms of cerebral palsy. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 71-78.	0.1	2
132	Pharmacoeconomic analysis of the medicinal product javlor (vinflunine) in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 86-90.	0.1	1
133	Pharmacoeconomic analysis of different types of treatment for spastic forms of cerebral palsy. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 71-78.	0.1	2
134	Pharmacoeconomic analysis of eviplera (rilpivirine/ tenofovir/ emtricitabine) in the treatment of hiv/aids in the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 44-51.	0.1	0
135	Pharmacoeconomic analysis of the medicinal product javlor (vinflunine) in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 86-90.	0.1	1
136	A pharmacoeconomic analysis of ibrutinib in the treatment of mantle cell lymphoma. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 31-34.	0.1	0
137	Pharmacoeconomic analysis of the use of gazyva (obinutuzumab) for the treatment of chronic lymphocytic leukemia in the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 61-65.	0.1	0
138	Pharmacoeconomic analysis of dasatinib as a second-line therapy in patients with chronic myelogenous leukemia. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 92-95.	0.1	1
139	Pharmacoeconomic analysis of kadcyla (trastuzumab emtansine) in the treatment of patients with her2-positive breast cancer. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 28-31.	0.1	0
140	Economic burden of multiple sclerosis in the Republic of Belarus. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 96-101.	0.1	1
141	Validation of the pharmacoeconomic model of emtricitabin/ rilpivirine/ tenofovir (eviplera) inclusion in highly active antiretroviral therapy of HIV/AIDS in the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 86-87.	0.1	0
142	Pharmacoeconomic analysis of beyodyme (pertuzumab+ trastuzumab [set]) in the treatment of patients with her2- positive metastatic breast cancer. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 36-39.	0.1	1
143	Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens. <i>Onkourologiya</i> , 2015, 11, 40.	0.3	0
144	Pharmacoeconomics study of canakinumab in patients with cryopyrin-associated periodic syndromes		

#	ARTICLE	IF	CITATIONS
145	Pharmacoeconomic study of buserelin-depo in the treatment of hormone-dependent prostate cancer. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 44-47.	0.1	0
146	Pharmacoeconomic analysis of von willebrand factor/blood clotting factor viii concentrate (wilate) in the management of patients with von willebrand disease. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 74-81.	0.1	1
147	Pharmacoeconomic analysis of implementation of clotting factor VIII and von Willenbrand factor medical products into the treatment regimens for von Willebrand disease. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 20-24.	0.1	0
148	Assessing willingness-to-pay threshold for health technologies in the Russian Federation on the basis of purchasing power parity. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 10-14.	0.1	1
149	Pharmacoeconomic study of canagliflozin (invocana) therapy as a part of combined therapy for patients with type 2 diabetes mellitus. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 55-61.	0.1	0
150	The cost-effectiveness of abatacept compared to adalimumab for adult patients with rheumatoid arthritis in the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 31-36.	0.1	1
151	Pharmacoeconomic evaluation of targeted therapy in patients with systemic lupus erythematosus. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 98-102.	0.1	0
152	Pharmacoeconomic analysis of treatment of patients with severe and moderate ischemic stroke (NIHSS) Tj ETQq0 0,0 rgBT /Qverlock 10	0.1	0
153	Pharmacoeconomic analysis of ryzodegÂ®, a combination of soluble ultra-long-acting human insulin analogue (insulin degludec) and ultra-short insulin analogue (insulin aspart), use in therapy of type 2 diabetes. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 61-66.	0.1	0
154	Long-Term Modeling of Using Manually Coded and Autocoded Blood Glucose Meters in Diabetes Treatment. <i>Value in Health</i> , 2014, 17, A333.	0.3	0
155	Budget Impact Evaluation Of Treatment With A Low Protein Diet And Ketoanalogues Of Essential Aminoacids For Predialysis Patients In Russian Federation. <i>Value in Health</i> , 2014, 17, A467.	0.3	0
156	Pharmacoeconomic Analysis Tofacitinib Use in Rheumatoid Arthritis Treatment Scheme. <i>Value in Health</i> , 2014, 17, A381.	0.3	3
157	Cost Analysis In the Treatment of Patients With Systemic Lupus Erythematosus In Russian Federation. <i>Value in Health</i> , 2014, 17, A527.	0.3	0
158	Pharmacoeconomic Study of Botulinium Toxin Type a in Treatment of Post-Stroke Spasticity in the Russian Federation: Cost-Effectiveness Analysis. <i>Value in Health</i> , 2014, 17, A395.	0.3	0
159	Pharmacoeconomic Analysis of Axitinib as Second-Line Treatment for Metastatic Renal Cell Carcinoma. <i>Value in Health</i> , 2014, 17, A638-A639.	0.3	1
160	Cost-Effectiveness Analysis of Autocoded and Manually Coded Blood Glucose Meters In Diabetes Treatment. <i>Value in Health</i> , 2014, 17, A337-A338.	0.3	0
161	Budget Impact Analysis of Bevacizumab and Anti-Egfr with Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation. <i>Value in Health</i> , 2014, 17, A75.	0.3	0
162	Cost Of Illness Analysis Of Dialysis In Different Regions Of Russia. <i>Value in Health</i> , 2014, 17, A292-A293.	0.3	0

#	ARTICLE	IF	CITATIONS
163	Pharmacoeconomic Assessment Of Treatment With A Low Protein Diet And Ketoanalogues Of Essential Aminoacids For Predialysis Patients In Russian Federation. Value in Health, 2014, 17, A291.	0.3	0
164	Budget Impact Analysis of Bevacizumab Plus Chemotherapy Versus Bevacizumab and Anti-Egfr With Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation. Value in Health, 2014, 17, A75.	0.3	1
165	Pharmacoeconomic analysis of first-line chemotherapy for advanced non-small cell lung cancer. Pharmacoeconomics Theory and Practice, 2014, 2, 25-28.	0.1	1
166	Pharmacoeconomic analysis of crizotinib use in first-line chemotherapy for alk-positive non-small cell lung cancer. Pharmacoeconomics Theory and Practice, 2014, 2, 25-28.	0.1	1
167	Pharmacoeconomics for the Health Care Managers: decision-making algorithm based on pharmacoeconomic assessments. Pharmacoeconomics Theory and Practice, 2014, 2, 13-20.	0.1	2
168	Pharmacoeconomic analysis of insulin analogues in the treatment of diabetes mellitus type 2. Pharmacoeconomics Theory and Practice, 2014, 2, 67-70.	0.1	0
169	Pharmacoeconomic Analysis of Insulin Degludec (Tresiba®) Use in Basal therapy of Type 2 Diabetes. Pharmacoeconomics Theory and Practice, 2014, 2, 32-34.	0.1	0
170	Pharmacoeconomic study of botulinum toxin type A in treatment of post-stroke spasticity in the upper limb. Pharmacoeconomics Theory and Practice, 2014, 2, 38-46.	0.1	0
171	Pharmacoeconomic evaluation of axitinib introduction in metastatic renal cell carcinoma treatment scheme. Pharmacoeconomics Theory and Practice, 2014, 2, 77-81.	0.1	0
172	Pharmacoeconomic evaluation of Sitagliptin compared to sulfonylurea derivatives in patients with type 2 diabetes not controlled by Metformin monotherapy. Pharmacoeconomics Theory and Practice, 2014, 2, 51-54.	0.1	0
173	Financing of healthcare system at the regional level. Interrelation of qualitative and quantitative parameters with the scope of healthcare financing. Pharmacoeconomics Theory and Practice, 2014, 2, 75-80.	0.1	0
174	Pharmacoeconomic study of herceptin® (trastuzumab) for breast cancer patients. Pharmacoeconomics Theory and Practice, 2014, 2, 50-53.	0.1	0
175	Methodological basics of modeling in the pharmacoeconomic studies: different levels of complexity and different value of the results obtained. Pharmacoeconomics Theory and Practice, 2014, 2, 16-22.	0.1	0
176	Pharmacoeconomic analysis of modern Insulin analogues in the treatment of diabetes mellitus type 2. Pharmacoeconomics Theory and Practice, 2014, 2, 67-70.	0.1	0
177	Pharmacoeconomic study of botulinum toxin type A in treatment of post-stroke spasticity in the upper limb. Pharmacoeconomics Theory and Practice, 2014, 2, 38-46.	0.1	0
178	Pharmacoeconomic evaluation of axitinib introduction in metastatic renal cell carcinoma treatment scheme. Pharmacoeconomics Theory and Practice, 2014, 2, 77-81.	0.1	0
179	Pharmacoeconomic evaluation of Sitagliptin compared to sulfonylurea derivatives in patients with type 2 diabetes not controlled by Metformin monotherapy. Pharmacoeconomics Theory and Practice, 2014, 2, 51-54.	0.1	0
180	Financing of healthcare system at the regional level. Interrelation of qualitative and quantitative parameters with the scope of healthcare financing. Pharmacoeconomics Theory and Practice, 2014, 2, 75-80.	0.1	0
180	Pharmacoeconomic study of herceptin® (trastuzumab) for breast cancer patients. Pharmacoeconomics Theory and Practice, 2014, 2, 50-53.	0.1	0

#	ARTICLE	IF	CITATIONS
181	Budget impact analysis of quetiapine versus aripiprazole or olanzapine on the top of standard therapy in the treatment of bipolar disorder in Russian Federation. Value in Health, 2013, 16, A58.	0.3	0
182	Comparative Pharmacoeconomic Analysis Of Budesonide/Formoterol Maintenance And Reliever Therapy In The Treatment Of Bronchial Asthma In Russian Federation. Value in Health, 2013, 16, A235-A236.	0.3	0
183	Pharmacoeconomic Study of Nutrition Support (NS) Usage During Intensive Treatment. Value in Health, 2013, 16, A379.	0.3	0
184	The Review of Publications of Pharmacoeconomic Research in Russia During 2007-2012. Value in Health, 2013, 16, A580.	0.3	0
185	Budget Impact Analysis (Bia) Of Cabazitaxel Introduction In Treatment Of Metastatic Hormone-Refractory Prostate Cancer (Mhrpc) In Russian Federation. Value in Health, 2013, 16, A132.	0.3	0
186	Pharmacoeconomic Assessment of Ranibizumab in the Treatment of the Diabetic Retinopathy in the Russian Federation. Value in Health, 2013, 16, A503.	0.3	0
187	Cost-Effectiveness of Antimicrobials as Treatment for Patients with Complicated Skin and Soft Tissues Infections: A Comparison Between Ceftaroline, Linezolid and Vancomycin in the Russian Health Care. Value in Health, 2013, 16, A355.	0.3	0
188	Peritonitis Fluid Treatment in Russian Federation: Evaluation of Economical Burden in Real Clinical Practice. Value in Health, 2013, 16, A494.	0.3	0
189	Budget Impact Analysis of Switching from DPT and Monovalent Vaccines to DTaPâ€“IPV-Hib Combined Vaccine into Russian Immunization Schedule. Value in Health, 2013, 16, A343.	0.3	0
190	Cost-effectiveness of atypical antipsychotics as treatment for patients with bipolar disorder (episodes) Tj ETQq0 0 0 rgBT /Overlock 10 T the Russian health care. Value in Health, 2013, 16, A61-A62.	0.3	0
191	Cost-effectiveness of atypical antipsychotics for the treatment of relapse prevention for bipolar disorder: The russian perspective. Value in Health, 2013, 16, A62.	0.3	0
192	Pharmacoeconomic Analysis of Anti-Inhibitor Coagulant Complex (AICC) in the Treatment of Inhibitor Hemophilia. Value in Health, 2013, 16, A379.	0.3	1
193	Economic Evaluation of Liraglutide for Treatment of Type 2 Diabetes Mellitus in the Russian Federation. Value in Health, 2013, 16, A443.	0.3	0
194	Budget Impact Analysis of Ceftaroline Versus Linezolid or Vancomycin on the Top of Standard Therapy in the Treatment of Complicated Skin and Soft Tissues Infections in Russian Federation. Value in Health, 2013, 16, A345.	0.3	0
195	Pharmacoeconomic Analysis Of Docetaxel In The Adjuvant Therapy Of Breast Cancer. Value in Health, 2013, 16, A132.	0.3	0
196	The cost-effectiveness of quetiapine, aripiprazole or olanzapine in patients with bipolar depression in the Russian Federation. Value in Health, 2013, 16, A62.	0.3	0
197	The economic burden of multiple sclerosis. Pharmacoeconomics Theory and Practice, 2013, 1, 3-34.	0.1	1
198	PCN82 Pharmacoeconomical Evaluation of Multiple Mieloma Treatment With Lenalidomide in the Russian Federation. Value in Health, 2012, 15, A222.	0.3	0

#	ARTICLE	IF	CITATIONS
199	PCN80 Economic Evaluation of Sunitinib for the First-Line Treatment of Metastatic Renal Cell Carcinoma in Russian Federation. Value in Health, 2012, 15, A222.	0.3	0
200	PIH8 Comparative Pharmacoeconomic Study of Disposable and Reusable Gowns and Drapes. Value in Health, 2012, 15, A537.	0.3	0
201	PRS12 Budget Impact Analysis of Tiotropium Bromide Versus Ipratropium Bromide on the Top of Standard Therapy in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) in Russian Federation. Value in Health, 2012, 15, A53.	0.3	0
202	PCV52 Urapidil in Treatment of Hypertension Urgencies in the Russian Federation: Cost-Effectiveness Analysis. Value in Health, 2012, 15, A121.	0.3	0
203	PIN54 Evaluation of Skin Tests in the Diagnostics of Tuberculosis Infection. Value in Health, 2012, 15, A395.	0.3	0
204	PCN79 Pharmacoeconomic Evaluation of Acute Myeloid Leukemia and MDS Syndromes (Intermediate) Tj ETQq0 0 0 rBT /Overlock 10 T	0.3	0
205	PCN92 Cost-Effectiveness of Nilotinib Versus Imatinib as First-Line Treatment for Newly Diagnosed Patients With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in the Chronic Phase (CML-CP) in Russian Federation. Value in Health, 2012, 15, A426.	0.3	0
206	PCV21 Budget Impact Analysis of Introducing of pCMV-VEGF165 for Treatment of Critical Limb Ischemia From the Russian Health Care System Perspective. Value in Health, 2012, 15, A365.	0.3	0
207	PND21 Multiple Sclerosis in Russian Federation: Evaluation of Social and Economical Burden in Real Clinical Practice. Value in Health, 2012, 15, A549.	0.3	1
208	PND43 Cost-Utility Analysis Patients With Low Back Pain After Treatment Intraosseous Blockades. Value in Health, 2012, 15, A553.	0.3	0
209	PSS6 Pharmacoeconomic Evaluation of Open-Angle Glaucoma Treatment in Russia. Value in Health, 2012, 15, A250.	0.3	0
210	PCN90 Cost-Effectiveness Analysis of Erlotinib Versus Docetaxel, Pemetrexed for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Russia. Value in Health, 2011, 14, A450.	0.3	2
211	PCN91 Pharmacoeconomic Analysis of mCRC Therapy With XELOX/FOLFOX4 Regimes With Bevacizumab or Cetuximab as the First Line Treatment in Russia. Value in Health, 2011, 14, A450-A451.	0.3	0
212	PCN46 Cost of Metastatic Prostate Cancer Treatment in the 12 Months Following Diagnosis per Patient in Russian Federation. Value in Health, 2011, 14, A442.	0.3	0
213	PRS47 Optima Model-Based Cost-Utility Analysis of Fixed Combination Salmeterol/Fluticasone Versus Non-Fixed Combination Budesonide/Formoterol in One Pack for Bronchial Asthma Treatment. Value in Health, 2011, 14, A496.	0.3	0
214	PCN61 COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER. Value in Health, 2011, 14, A165.	0.3	0
215	PMS25 Evaluation of Direct Costs for the Treatment of Active Juvenile Rheumatoid Arthritis Using Biologics. Value in Health, 2011, 14, A306.	0.3	2
216	PGI20 Pharmacoeconomic Study of Glutamine Dipeptide Usage During Total Parenteral Nutrition (TPN). Value in Health, 2011, 14, A395.	0.3	0

#	ARTICLE	IF	CITATIONS
217	PRS37 The Impact of Regional Data on Cost-Effectiveness Results of Salmeterol/Fluticasone Propionate (SAL/FP) + Fenoterol/Ipratropium Bromide (Fen/IB) Versus Fen/IB Only in COPD Treatment. Value in Health, 2011, 14, A494.	0.3	0
218	PCN55 COST OF TREATMENT OF BREAST CANCER IN RUSSIA. Value in Health, 2010, 13, A261.	0.3	1
219	PCN87 PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT. Value in Health, 2010, 13, A267.	0.3	0
220	PDB49 PHARMACOECONOMICS MODELING OF LONG TERM RESULTS OF TYPE 2 DIABETES MELLITUS TREATMENT IN PATIENTS USING MODERN INSULIN ANALOGUES IN CONTRAST TO ORAL ANTIDIABETIC DRUGS OR DIET. Value in Health, 2010, 13, A292.	0.3	0
221	PRS31 SHOULD SALMETEROL/FLUTICASONE PROPIONATE (SAL/FP) BE ADDED TO ROUTINE COPD TREATMENT WITH FENOTEROL/ IPRATROPIUM BROMIDE (FEN/IB)? PHARMACOECONOMIC ASSESSMENT OF COPD TREATMENT BASED ON OBSERVATIONAL RESEARCH (PHACTOR). Value in Health, 2010, 13, A324.	0.3	0
222	PRS32 REGIONAL DIFFERENCES AS A BASIS FOR SENSITIVITY ANALYSIS OF COST-EFFECTIVENESS OF SALMETEROL + FLUTICASONE PROPIONATE (SAL/FP) VS. INHALED CORTICOSTEROIDS (MONO-ICS). Value in Health, 2010, 13, A324.	0.3	0
223	PND23 COST-EFFECTIVENESS EVALUATION OF LEVODOPA/CARBIDOPA/ ENTACAPONE IN TREATMENT OF PARKINSON DISEASE. Value in Health, 2010, 13, A392.	0.3	0
224	Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogs in comparison with oral hypoglycemic agents. Diabetes Mellitus, 2010, 13, 101-110.	1.9	1
225	PRS8 OPTIMA MODEL-BASED COST-UTILITY ANALYSIS OF FIXED COMBINATIONS SALMETEROL/FLUTICASONE VS. BUDESONIDE/FORMOTEROL IN TREATMENT OF ASTHMA IN RUSSIA. Value in Health, 2009, 12, A300.	0.3	1
226	PRS15 NEW PHARMACOECONOMIC MODEL OF ASTHMA MAINTENANCE TREATMENT (OPTIMA) IN RUSSIA. TO TREAT OR NOT TO TREAT: MAINTENANCE TREATMENT VS. NO MAINTENANCE TREATMENT. Value in Health, 2009, 12, A301.	0.3	0
227	PSY29 PHARMACOECONOMIC EVALUATION OF TREATMENT ANEMIA WITH ERYTHROPOIETIC AGENTS IN CHRONIC KIDNEY DISEASE PATIENTS. Value in Health, 2009, 12, A380.	0.3	0
228	PHC2 IMPACT OF LOCAL HAEMOSTATIC AGENTS IN ABDOMINAL SURGERY ON HOSPITAL BUDGET. Value in Health, 2008, 11, A531-A532.	0.3	0
229	PCV29 PHARMACOECONOMIC ANALYSIS OF EXTENDED PROPHYLAXIS BY ENOXAPARIN AFTER HIP JOINT REPLACEMENT. Value in Health, 2007, 10, A45.	0.3	0
230	PND7 PHARMACOECONOMIC ANALYSIS OF ANTIEPILEPTIC DRUGS IN THE TREATMENT OF THE IDIOPATHIC GENERALIZED EPILEPSIES. Value in Health, 2007, 10, A88.	0.3	0
231	PIN20 PHARMACOECONOMIC ANALYSIS OF SEVERE COMMUNITYACQUIRED PNEUMONIA TREATMENT. Value in Health, 2007, 10, A165.	0.3	0
232	PUK5 RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUNÂ® NEORALÂ®) IN COMPARISON WITH CYCLOSPORINE A GENERICS FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION. Value in Health, 2007, 10, A314.	0.3	0
233	PUK6 RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUNÂ® NEORALÂ®) IN COMPARISON WITH TACROLIMUS (PROGRAFÂ®) FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION. Value in Health, 2007, 10, A314-A315.	0.3	0
234	Development and validation of reversed phase high performance liquid chromatography method for determination of dexpanthenol in pharmaceutical formulations. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 983-988.	2.8	13

#	ARTICLE	IF	CITATIONS
235	PHP36 PHARMACOEPIDEMOLOGICAL ANALYSIS OF THE USEING DRUGS FROM REIMBESMENT LIST IN RUSSIA. Value in Health, 2006, 9, A218.	0.3	0
236	PIN4 ANTIBIOTIC THERAPY OF NOSOCOMIAL INFECTION IN THE INTENSIVE CARE UNIT: A COST-EFFECTIVENESS ANALYSIS. Value in Health, 2006, 9, A299.	0.3	1
237	PAA4 PHARMACOECONOMIC ANALYSIS OF USE OF A SIMBICORT TURBUHALER AND SERETIDE MULTIDISK OF ASTHMA PATIENTS. Value in Health, 2006, 9, A333.	0.3	0